Our Keynote kidney cancer clinical trials are studying pembrolizumab to see if it may help patients with renal cell carcinoma (RCC), including clear cell and non-clear cell RCC. Pembrolizumab is an investigational immunotherapy that works by blocking the PD-1 pathway.
Pembrolizumab has been FDA-approved for use in certain types of cancer.
Clinical trials for renal cell carcinoma (RCC) are underway and currently enrolling patients. If you have patients with RCC, you may want to consider a Keynote trial. To see if your patients qualify for one of these trials, contact our clinical trial information center at 1-888-577-8839. If you are interested in partnering with us as an investigator, call 1-800-290-4339.
|Trial Description||Keynote Trial||Condition||Phase||Status|
|Safety and Efficacy Study of Pembrolizumab as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy||564||Renal Cell Carcinoma||Phase 3||Recruiting|
|Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma||426||Renal Cell Carcinoma||Phase 3||Active, not recruiting|
|Study of Pembrolizumab Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma||427||Renal Cell Carcinoma||Phase 2||Active, not recruiting|